Evidence map›Paper›PMID 30119630›Full record

ArticleBMC health services research2018

Modeling patient access to therapeutic oxytocin in Zanzibar, Tanzania.

Devika Nadkarni, Sara Gravelyn, Monica Brova, Sarem Rashid, Randy Yee, Donovan Guttieres, Katie Clifford, Darash Desai, Muhammad Zaman

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Devika NadkarniDepartment of Biomedical Engineering, Boston University, 38 Cummington Street, Boston, MA, 02215, USA.
Sara GravelynDepartment of Biomedical Engineering, Boston University, 38 Cummington Street, Boston, MA, 02215, USA.
Monica BrovaDepartment of Biomedical Engineering, Boston University, 38 Cummington Street, Boston, MA, 02215, USA.
Sarem RashidDepartment of Biomedical Engineering, Boston University, 38 Cummington Street, Boston, MA, 02215, USA.
Randy YeeDepartment of Biomedical Engineering, Boston University, 38 Cummington Street, Boston, MA, 02215, USA.
Donovan GuttieresDepartment of Biomedical Engineering, Boston University, 38 Cummington Street, Boston, MA, 02215, USA.
Katie CliffordDepartment of Biomedical Engineering, Boston University, 38 Cummington Street, Boston, MA, 02215, USA.
Darash DesaiDepartment of Biomedical Engineering, Boston University, 38 Cummington Street, Boston, MA, 02215, USA.
Muhammad ZamanDepartment of Biomedical Engineering, Boston University, 38 Cummington Street, Boston, MA, 02215, USA. zaman@bu.edu.
Boston University · US

Funding

Translational Research in BiomaterialsT32EB006359 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI MARK W. GRINSTAFF, Michelle H Teplensky · 2009 to 2026
$4.2M
NIBIB NIH HHS T32 EB006359
6 · The paper itself

Abstract

backgroundOur objective is to estimate the effects of therapeutic oxytocin supply chain factors and social determinants of health on patient access to oxytocin in low-income settings using system dynamics modeling. Postpartum hemorrhage (PPH), a major cause of maternal mortality disproportionately affects women in low and middle income countries (LMICs). The World Health Organization recommends therapeutic oxytocin as the frontline uterotonic for PPH management and prevention. However, lack of access to quality therapeutic oxytocin in Tanzania, and throughout Sub-Saharan Africa, continues to result in a high number of preventable maternal deaths.

methodsWe used publicly available data from Zanzibar and Sub-Saharan Africa, literature review, oxytocin degradation kinetics and previously developed systems dynamics models to understand the barriers in patient access to quality therapeutic oxytocin.

resultsThe model makes four basic predictions. First, there is a major gap between therapeutic oxytocin procurement and availability. Second, it predicts that at current population increase rates, oxytocin supply will have to be doubled in the next 30 years. Third, supply and storage temperature until 30 °C has minimal effect on oxytocin quality and finally distance of 5 km or less to birthing facility has a small effect on overall access to oxytocin.

conclusionsThe model provides a systems level approach to therapeutic oxytocin access, incorporating supply and procurement, socio-economic factors, as well as storage conditions to understand how women's access to oxytocin over time can be sustained for better health outcomes.

Indexed as

Health Services AccessibilityModels, OrganizationalAdultDrug StorageFemaleHumansMaternal MortalityOxytocicsOxytocinPostpartum HemorrhagePregnancyTanzaniaOxytocicsOxytocin

Identifiers

PMID30119630
PMCPMC6098590
OpenAlexW2886733083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.